logo

For the Inventor, By the Inventor

Jinan, China

Frank Wu

This inventor holds 17 USPTO granted patents and 9 EPO patents, primarily in Kinase Inhibitors. Top assignees: Xuanzhu Pharma Co., Ltd., Sihuan Pharmaceutical Holdings Group Ltd., Suanzhu Pharma Co., Ltd.. Active years: 2015-2019.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Frank Wu. Retrieved from https://idiyas.com/inventor/frank-wu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 17

% Patents Active = 82.4

 

Average Co-Inventor Count = 1.4

ph-index = 3

Forward Citations = 17(Granted Patents)


Location History:

  • Shandong Province, CN (2017)
  • Shandong, CN (2015 - 2018)
  • Jinan, CN (2016 - 2019)

Company Filing History:

goldMedal14 out of 28 
 
Xuanzhu Pharma Co., Ltd.
 patents
silverMedal4 out of 4 
 
Sihuan Pharmaceutical Holdings Group Ltd.
 patents
bronzeMedal1 out of 1 
 
Suanzhu Pharma Co., Ltd.
 patent
4. 1 out of 1 
 
Zuanzhu Pharma Co., Ltd.
 patent
where one patent can have more than one assignee

Years Active: 2015-2019

Loading Chart...
Loading Chart...
Areas of Expertise:
Tyrosine Kinase Inhibitor
C-Glycoside Derivative
Beta-Lactamase Inhibitors
Anaplastic Lymphoma Kinase
Quinazoline Derivative
Optically Pure Benzyl Derivative
Dual PI3K Inhibitor
Biaryl Heterocycle
Pyridonaphthyridine
Substituted Pyrimidine
Tumor Necrosis Factor Alpha
Phosphodiesterase 4 Inhibitors
17 patents (USPTO):Explore Patents
1. 10300058 - Tyrosine kinase inhibitor and uses thereof (2019-05-28),
2. 10253010 - C-glycoside derivative (2019-04-09),
3. 10167283 - β-lactamase inhibitors and uses thereof (2019-01-01),
4. 10011592 - Polycyclic inhibitor of anaplastic lymphoma kinase (2018-07-03),
5. 9956222 - Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof (2018-05-01),
6. 9949976 - Kinase inhibitor and use thereof (2018-04-24),
7. 9914688 - Optically pure benzyl-4-chlorophenyl-C-glucoside derivative (2018-03-13),
8. 9796701 - Kinase inhibitor and use thereof (2017-10-24),
9. 9586939 - Quinazoline derivative as tyrosine-kinase inhibitor, preparation method therefor and application thereof (2017-03-07),
10. 9562029 - C-glycoside derivatives (2017-02-07),
11. 9475812 - Pyridonaphthyridine type dual PI3K and mTOR inhibitor and its preparation and use (2016-10-25),
12. 9365572 - PI3K and/or mTOR inhibitor (2016-06-14),
13. 9359371 - Bicyclic substituted pyrimidine compounds (2016-06-07),
14. 9359344 - Biaryl heterocycle substituted oxazolidinone antibacterial agents (2016-06-07),
15. 9315438 - Optically pure benzyl-4-chlorophenyl-C-glucoside derivative (2016-04-19),

Title: **Frank Wu: Innovator in Pharmaceutical Research**

Introduction

Frank Wu is a notable inventor based in Jinan, China, recognized for his significant contributions to pharmaceutical sciences. With a remarkable portfolio of 17 patents, he has dedicated his career to advancing the field of medicinal chemistry, particularly in the development of compounds that target critical biological pathways.

Latest Patents

Among Wu's latest inventions is a novel **tyrosine kinase inhibitor**. This compound, represented by Formula (I), or its pharmaceutically acceptable salts, esters, or solvates, presents a promising avenue for treating diseases associated with the overactivity of epidermal growth factor receptor (EGFR), including certain types of cancer. The invention details not only the method for the compound's preparation but also a pharmaceutical composition and a kit that incorporates this innovative compound. Additionally, another recent patent focuses on a **C-glycoside derivative**, described by a general formula (I) that identifies various components of the compound, highlighting its potential applications in medical treatments.

Career Highlights

Frank Wu has made substantial strides in the pharmaceutical industry through his work at Xuanzhu Pharma Co., Ltd. and Sihuan Pharmaceutical Holdings Group Ltd. His expertise in drug development has positioned him as a leading figure in creating therapeutic solutions that address critical medical needs.

Collaborations

Throughout his career, Wu has collaborated with talented professionals like Aichen Wang and Yan Zhang. These partnerships demonstrate the collective effort in driving innovations that can potentially transform patient care and treatment methodologies across the globe.

Conclusion

In conclusion, Frank Wu stands out as a prominent inventor in the field of pharmaceuticals. His dedication to research and development has led to breakthrough patents that enhance our understanding and treatment of diseases linked to tyrosine kinase activity. As he continues to innovate, his work promises to inspire future generations of researchers and inventors.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…